Johnson & Johnson To Pay More Than $1.6 Billion To Resolve Healthcare Fraud Allegations

Monday, November 4, 2013

Tennessee will receive more than $12 million as part of a multistate and federal agreement resolving allegations pharmaceutical manufacturer Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., used deceptive marketing tactics. Specifically, the parties will pay $1.6 billion to resolve civil and criminal allegations of unlawful marketing practices to promote the sales of their atypical antipsychotic drugs, Risperdal and Invega. 

J&J and Janssen will pay in excess of $1.2 billion to the states and the federal government to resolve four qui tam, or whistleblower, lawsuits filed in the U.S. District Court for the Eastern District of Pennsylvania under the provisions of the federal False Claims Act and similar state False Claims statutes. In addition, Janssen Pharmaceuticals, Inc. will plead guilty in federal court to a criminal misdemeanor charge of misbranding Risperdal in violation of the Food, Drug, and Cosmetic Act.  As part of the criminal plea, Janssen has agreed to pay an additional $400 million in criminal fines and forfeitures.

“We applaud the cooperative work of the states and federal government to stop drug companies from illegally marketing potentially dangerous drugs to the public,” Tennessee Attorney General Bob Cooper said.  “The public needs to be able to trust those responsible for their health and well-being, and that includes drug manufacturers and those who prescribe medications.” 

J & J and Janssen allegedly promoted, marketed and introduced Risperdal and Invega into interstate commerce for uses not approved by the Food and Drug Administration and for uses that were not medically indicated.  Once the FDA approves a drug as safe and effective, a manufacturer cannot market or promote a drug for an “off-label” or other use not identified in the FDA-approved product label.  The states contend that during the period Jan. 1, 1999 through Dec. 31, 2005, the companies promoted Risperdal for off-label uses and made false and misleading statements about the safety and efficacy of Risperdal.

The states additionally allege J&J and Janssen paid illegal kickbacks to health care professionals and long-term care pharmacy providers to induce them to promote or prescribe Risperdal to children, adolescents and the elderly when there was no FDA approval for Risperdal use in these patient populations. The states further contend that from Jan. 1, 2007 through Dec. 31, 2009, the companies promoted Invega for off-label uses and made false and misleading statements about the safety and efficacy of Invega.  The manufacturers’ alleged unlawful conduct caused false and/or fraudulent claims to be submitted to or caused purchases by government funded health care programs, including the state Medicaid programs. 

As part of the global resolution, the companies will enter into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services, Office of the Inspector General, which will monitor the company’s future marketing practices.

A team from the National Association of Medicaid Fraud Control Units worked with the federal government on the investigation and conducted the settlement negotiations with the pharmaceutical manufacturers on behalf of the states.  Team members included representatives from the Offices of the Attorneys General for the states of New York, Massachusetts, Ohio and California.

Alexander, Murray Introduce Budget Amendment For Medical Treatments To Reach American Patients

Senate health committee Chairman Lamar Alexander and Ranking Member Patty Murray (D-Wash.) Thursday introduced a budget amendment to promote the research, development, and approval or licensure of the "most cutting-edge, safe and effective medical treatments, devices, and cures for American patients and to ensure that America remains the global leader in biomedical innovation."  ... (click for more)

Ooltewah Medical Services Set To Open At Cambridge Square On Monday

Ooltewah Medical Services, A SkyRidge Health Partner, is set to open its doors on Monday to the Ooltewah/Collegedale community at the new Cambridge Square Development.   “We are very excited about this clinic opening in Ooltewah as it is our continued mission to serve the needs of patients in neighboring communities by providing quality healthcare”, states Coleman Foss, ... (click for more)

Robber Is Shot By Victim In Attempted Robbery On East 43rd Street

One person was shot during a robbery attempt at 4314 Rossville Blvd. around 1:50 p.m. on Thursday.  The Chattanooga Police Department is investigating the robbery that ended in a shooting near East 43rd St. at Miller Auto Sales.  The robbery victim shot the suspect.  The suspect was taken to the hospital for treatment of injuries. Chattanooga ... (click for more)

Fire On Crutchfield Street Ruled Arson

Chattanooga fire investigators have determined that last Thursday’s fire at 1207 Crutchfield St.  that nearly killed four people was deliberately set. Lt. Henry McElvain with the Fire Investigation Division said he cannot divulge the reason why he thinks it’s arson, but he is asking for help from the public. If anyone has information that can help solve this case, call ... (click for more)

The Problems With Prescription Drug Addiction

In Tennessee today, we have a major problem with prescription drug addiction, particularly when powerful opioid pain relievers are concerned.    For the first time in 2012, Tennesseans abused prescription opioid drugs more than alcohol.  Our young people ages 18-25 abuse prescription opioids at a 30 percent higher rate than the national average.  In just five ... (click for more)

Roy Exum: I Recall J.C. Owens

If you were to go to Oakville, Ala, a little ways from Decatur, about the biggest thing you’d find would be some 20 or so Indian mounds, where the early tribes would bury their dead many centuries ago. But if you sniffed around a bit, you’d learn it was the birthplace of James Cleveland Owens, a man whose name is of no consequence to anyone. I’m proud to say I talked to him ... (click for more)